QuikPath

QuikPath

Increasing access to diagnostics through rapid, easy-to-use, and affordable isothermal RT-PCR point-of-care kits!

Founded 2019

Singapore 1 employees Biotechnology

QuikPath is a Singapore-based biotechnology startup founded in 2019. The company's slogan, "Increasing access to diagnostics through rapid, easy-to-use, and affordable isothermal RT-PCR point-of-care kits!", encapsulates its core mission. QuikPath has developed a home PCR test for Covid-19 that delivers results in just 30 minutes. This innovative solution is designed within a simple-to-use cartridge, which accepts sample swabs and produces a color change to indicate results. Notably, QuikPath's technology is the only simple and scalable method to detect early-stage infections. In light of the burgeoning need for rapid and accessible testing solutions, QuikPath's offering holds significant promise. The potential impact of the startup's products on public health and disease management is substantial, particularly amid the ongoing pandemic. As of now, there is no available information regarding QuikPath's last investment or the involved investors, which may indicate that the company is either self-funded or in the early stages of raising capital. The biotechnology industry, in which QuikPath operates, is ripe for innovation and disruption, and the demand for cutting-edge diagnostic tools is on the rise. The startup's focus on democratizing access to critical diagnostics aligns with market trends and societal needs. Given QuikPath's novel approach, the company has the potential to attract considerable attention from investment firms seeking to support groundbreaking technologies with the power to transform healthcare delivery. Overall, QuikPath's combination of innovative technology, societal relevance, and potential market impact positions it as a compelling candidate for investment, provided that it continues to demonstrate strong execution and market traction.

FAQ About QuikPath

Increasing access to diagnostics through rapid, easy-to-use, and affordable isothermal RT-PCR point-of-care kits!

QuikPath was founded in 2019.

QuikPath is headquartered in Singapore.

QuikPath operates in Biotechnology. Its work centres on Diagnostics, Medtech, Infectious Diseases and Point-of-Care Testing.

QuikPath has approximately 1 employees.

Top alternatives and competitors to QuikPath include Senzo Health, FRIZ Biochem GmbH, UTI-lizer, MagIA diagnostics, EMPE Diagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

QuikPath and Senzo Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About QuikPath

QuikPath Alternatives & Competitors

FAQ About QuikPath